In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii

被引：20

作者：

Li, Houmin ^{[1
]}

Lu, Qiaoyun ^{[2
,3
]}

Wan, Zhe ^{[2
,3
]}

Zhang, Jianzhong ^{[1
]}

机构：

[1] Peking Univ, Peoples Hosp, Dept Dermatol, Beijing 100044, Peoples R China

[2] Peking Univ, Hosp 1, Dept Dermatol, Beijing 100044, Peoples R China

[3] Peking Univ, Res Ctr Med Mycol, Beijing 100044, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2010年 / 35卷 / 06期

基金：

北京市自然科学基金;

关键词：

Trichosporon asahii; Antifungal susceptibility; Drug interaction; COMBINATION; MICAFUNGIN; INFECTION; EFFICACY; BEIGELII;

D O I：

10.1016/j.ijantimicag.2010.01.013

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Disseminated infections caused by Trichosporon asahii are difficult to resolve. Combination regimens with synergistic drugs could provide additional options for treating trichosporonosis. The aim of this study was to evaluate the antifungal activities of voriconazole (VCZ), caspofungin (CAS) and amphotericin B (AMB) alone or in combination in vitro against clinical isolates of T. asahii. The combined antifungal activities of VCZ, CAS and AMB against 18 clinical isolates were assessed by a chequerboard microdilution method. CAS combined with AMB showed the highest percentage of synergistic effects (89%), much higher than those of the other two combinations (AMB/VCZ and CAS/VCZ both 17%). No antagonistic effect was observed in any case. This study demonstrates that the activity of two combined antifungals, especially the combination of CAS and AMB, against T. asahii is more effective than that of a drug alone against this fungus, suggesting that combined antifungal therapy may be a potential strategy for treating disseminated trichosporonosis. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：550 / 552

页数：3

共 13 条

[1]

[Anonymous], 2002, CLSI (NCCLS) M27-A2

[2] In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].

Arikan, S ;

Lozano-Chiu, M ;

Paetznick, V ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247

[3] Trichosporon beigelii infection:: experience in a regional burn center [J].

Cawley, MJ ;

Braxton, GR ;

Haith, LR ;

Reilly, KJ ;

Guilday, RE ;

Patton, ML .

BURNS, 2000, 26 (05) :483-486

[4] Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia [J].

Ebright, JR ;

Fairfax, MR ;

Vazquez, JA .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (05) :E28-E30

[5] Uncommon opportunistic fungi: new nosocomial threats [J].

Groll, AH ;

Walsh, TJ .

CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 :8-24

[6] Efficacy of amphotericin B and azoles alone and in combination against disseminated trichosporonosis in neutropenic mice [J].

Kamberi, P ;

Atsuro, H ;

Takayoshi, T ;

Masaru, N .

CHEMOTHERAPY, 1998, 44 (01) :55-62

[7] Trichosporon species infection in bone marrow transplanted patients [J].

Moretti-Branchini, ML ;

Fukushima, K ;

Schreiber, AZ ;

Nishimura, K ;

Papaiordanou, PMO ;

Trabasso, P ;

Tanaka, R ;

Miyaji, M .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 39 (03) :161-164

[8] In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula [J].

Serena, C ;

Mariné, M ;

Pastor, FJ ;

Nolard, N ;

Guarro, J .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (06) :1020-1023

[9] Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis [J].

Serena, C ;

Pastor, FJ ;

Gilgado, F ;

Mayayo, E ;

Guarro, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :497-502

[10]

Tokimatsu Issei, 2003, Nihon Ishinkin Gakkai Zasshi, V44, P181, DOI 10.3314/jjmm.44.181

← 1 2 →